# BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS

> clinical trial · VERIFIED · 2026-08-11

Status: COMPLETED · Sponsor: Groupe Francophone des Myelodysplasies · Condition: Myelodysplastic Syndromes

- Company: Groupe Francophone des Myelodysplasies
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT04827719

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.